Does Rallies show Form 4 insider transactions for KYMR?

Yes. Rallies tracks KYMR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KYMR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KYMR. It does not provide personalized investment advice.

KYMR (Kymera Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Kymera Therapeutics, Inc. Common Stock (KYMR) is a publicly traded Healthcare sector company. As of May 21, 2026, KYMR trades at $80.28 with a market cap of $6.55B and a P/E ratio of -21.86. KYMR moved +3.33% today. Year to date, KYMR is +11.38%; over the trailing twelve months it is +156.52%. Its 52-week range spans $19.45 to $103.00. Analyst consensus is strong buy with an average price target of $119.07. Rallies surfaces KYMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KYMR stock inside the company?

Recent KYMR insider activity includes Ridloff Elena sold 3.00K, Mainolfi Nello sold 17.00K, Mainolfi Nello sold 12.06K, Mainolfi Nello sold 936, and Booth Bruce sold 5.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KYMR Key Metrics

Key financial metrics for KYMR
Metric	Value
Price	$80.28
Market Cap	$6.55B
P/E Ratio	-21.86
EPS	$-3.69
Dividend Yield	0.00%
52-Week High	$103.00
52-Week Low	$19.45
Volume	321
Avg Volume	0
Revenue (TTM)	$39.21M
Net Income	$-311.35M
Gross Margin	0.00%

Recent KYMR Insider Trades

Ridloff Elena sold 3.00K (~$261.00K) on May 11, 2026.
Mainolfi Nello sold 17.00K (~$1.37M) on Apr 29, 2026.
Mainolfi Nello sold 12.06K (~$985.22K) on Apr 29, 2026.
Mainolfi Nello sold 936 (~$77.17K) on Apr 29, 2026.
Booth Bruce sold 5.90K (~$530.76K) on Apr 22, 2026.

Latest KYMR News

Kymera climbs as Fast Track KT-621 momentum and May conference catalysts fuel bid — May 6, 2026
Kymera’s KT-579 Matches JAK Inhibitors, Completely Blocks TNFα and IL-6 in IBD Model — May 5, 2026
Kymera climbs as Gilead milestone, big cash runway, May KT-621 catalysts refocus buyers — May 4, 2026
Kymera slides after Q1 results as investors weigh cash burn and R&D ramp — Apr 30, 2026
Kymera Nets $45M Milestone, $1.55B Cash Runway and KT-621 Phase 2b Progress — Apr 30, 2026

KYMR Analyst Consensus

16 analysts cover KYMR: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $119.07.

Common questions about KYMR

Who is trading KYMR stock inside the company?: Recent KYMR insider activity includes Ridloff Elena sold 3.00K, Mainolfi Nello sold 17.00K, Mainolfi Nello sold 12.06K, Mainolfi Nello sold 936, and Booth Bruce sold 5.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KYMR?: Yes. Rallies tracks KYMR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KYMR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KYMR. It does not provide personalized investment advice.